Vol 15, No 2 (2019)
Case report
Published online: 2019-05-17

open access

Page views 477
Article views/downloads 515
Get Citation

Connect on Social Media

Connect on Social Media

When to say “no” to a patient with an ovarian tumour and in poor general condition?

Kamila Kaźmierczak1, Joanna Kufel-Grabowska12, Tomasz Kozłowski3, Błażej Nowakowski14
Oncol Clin Pract 2019;15(2):132-134.

Abstract

Neuroendocrine tumours (NET) originating from the ovary are very rare, constituting about 0.52–1.7% of all NETs. Primary carcinoids constitute about 0.1% of ovarian tumours and 0.3% of all carcinoids. They rarely show hormonal activity. They are most often diagnosed post-operatively, based on pathomorphological examination using immunohistochemical methods. Due to the small number of cases, most information on the management of patients with this diagnosis comes from retrospective studies and case reports.

This paper presents a case report of a 63-year-old woman who was admitted to the department of surgical gynaecology with the diagnosis of a 15-cm right ovary tumour. Her general condition was poor due to severe respiratory failure and severe tricuspid valve insufficiency. The clinical picture and the performed echocardiographic examination aroused the suspicion of carcinoid heart disease (Hedinger syndrome — a cardiological syndrome of carcinoids). Due to the determination and cooperation of a multidisciplinary medical team, despite a very bad prognosis, the patient underwent surgery. Immediately after the operation, the patient’s condition was critical, but it gradually improved. In the postoperative pathomorphological examination, a highly differentiated neuroendocrine tumour (grade 1 – G1) was diagnosed at stage IA according to the FIGO classification. The patient was referred to the endocrinology department, where receptor scintigraphy was performed without revealing other tumour changes. The patient did not require adjuvant therapy. Making a decision about surgical treatment of a patient in poor physical condition with a possibly reversible cause of heart failure was the right thing to do, and it allowed her to return to normal physical activity.

Article available in PDF format

View PDF Download PDF file

References

  1. Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases. J Exp Clin Cancer Res. 2000; 19(3): 271–280.
  2. Talerman A. Germ cell tumor of the ovary. W: Blaunstein’s pathology of the female genital tract Kurman R (red). Springer-Verlag, New York 1993: 886–893.
  3. Kuc-Rajca M, Dańska-Bidzińska A. Współczesne zasady leczenia nowotworów neuroendokrynnych kobiecych narządów płciowych. Ginekol Pol. 2011; 82: 685–689.
  4. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003; 22(4): 517–530.
  5. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4): 934–959.
  6. Młodzianowski A. Zespół Hedingera – sercowe objawy zespołu rakowiaka. Choroby Serca i Naczyń. 2014; 11: 34–38.
  7. Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995; 25(2): 410–416.
  8. Møller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005; 112(21): 3320–3327.
  9. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993; 87(4): 1188–1196.
  10. Zalecenia ogólne dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych Polskiej Sieci Guzów Neuroendokrynnych 2017.
  11. Caowalit N, Conolly HM, Schaff HV, et al. Carcinoid heart disease associated with primary carcinoid heart disease. Am J Med. 1985; 79: 339–354.
  12. Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer. 1975; 36(2): 404–418.